Kidney Transplant Recipients Clinical Trial
Official title:
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy
Endothelial lesions within the transplanted kidney are a major determinant of chronic
allograft nephropathy. Epoxyeicosatrienoic acids (EETs) are endothelium-derived
hyperpolarizing factors with anti-inflammatory, antiproliferative and vasodilator
properties.
The main goal of the investigators' study is to evaluate whether genetic polymorphisms of
specific enzymes responsible for the bioavailability of EETs are associated with
post-transplant kidney function.
To this end, 80 kidney transplant recipients will be included. Prespecified genetic
polymorphisms of CYP 2J2, CYP 2C8, CYP 2C9, CYP 2C9, CYP 2C19 and EPHX2 will be determined.
Kidney function will be recorded 3, 6, 12 and 36 months after transplantation. Flow-mediated
dilatation, EETs and circulating biomarkers of endothelial function will be measured in the
radial artery.
The expected results of this study to provide preliminary evidence supporting a beneficial
role of an increase in the bioavailability of EETs in kidney transplant recipients.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01336296 -
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
|
Phase 4 | |
| Recruiting |
NCT01150487 -
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
|
N/A | |
| Recruiting |
NCT05938712 -
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
|
Phase 2 | |
| Completed |
NCT00217100 -
A Multivitamin Comparison Study in Kidney Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT00199667 -
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT01517984 -
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
|
Phase 2 | |
| Recruiting |
NCT04642833 -
Prostate Cancer in Renal Transplants Recipients
|
||
| Not yet recruiting |
NCT05293704 -
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01782586 -
Validation of Gene Expression Markers of Renal Allograft Functional Decline
|
||
| Enrolling by invitation |
NCT02042963 -
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)
|
N/A | |
| Not yet recruiting |
NCT05702398 -
Pilot Trial of Supplemental Vitamin A and Nicotinamide
|
Early Phase 1 | |
| Active, not recruiting |
NCT05425498 -
The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01889758 -
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
|
Phase 4 | |
| Terminated |
NCT02268201 -
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
|
Phase 4 | |
| Active, not recruiting |
NCT03979365 -
Envarsus XR Compared to Immediate Release Tacrolimus
|
Phase 4 | |
| Recruiting |
NCT04965935 -
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
|
Phase 3 | |
| Recruiting |
NCT04444843 -
Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen
|
Phase 4 | |
| Completed |
NCT02392312 -
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
|
||
| Completed |
NCT02639949 -
Measuring and Improving Medication Adherence in Kidney Transplant Patients
|
N/A | |
| Withdrawn |
NCT02058875 -
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
|
Phase 4 |